IL255831A - Inhibitors of bruton's tyrosine kinase - Google Patents
Inhibitors of bruton's tyrosine kinaseInfo
- Publication number
- IL255831A IL255831A IL255831A IL25583117A IL255831A IL 255831 A IL255831 A IL 255831A IL 255831 A IL255831 A IL 255831A IL 25583117 A IL25583117 A IL 25583117A IL 255831 A IL255831 A IL 255831A
- Authority
- IL
- Israel
- Prior art keywords
- bruton
- inhibitors
- tyrosine kinase
- tyrosine
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169945P | 2015-06-02 | 2015-06-02 | |
| US201562169935P | 2015-06-02 | 2015-06-02 | |
| US201562169941P | 2015-06-02 | 2015-06-02 | |
| US201562249336P | 2015-11-01 | 2015-11-01 | |
| US201562249338P | 2015-11-01 | 2015-11-01 | |
| US201562249340P | 2015-11-01 | 2015-11-01 | |
| PCT/US2016/035489 WO2016196776A2 (en) | 2015-06-02 | 2016-06-02 | Inhibitors of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL255831A true IL255831A (en) | 2018-01-31 |
Family
ID=57441893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL255831A IL255831A (en) | 2015-06-02 | 2017-11-21 | Inhibitors of bruton's tyrosine kinase |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180305348A1 (https=) |
| EP (1) | EP3310776A4 (https=) |
| JP (1) | JP2018522823A (https=) |
| KR (1) | KR20180021740A (https=) |
| CN (1) | CN107709315A (https=) |
| AU (2) | AU2016270907B2 (https=) |
| BR (1) | BR112017025986A2 (https=) |
| CA (1) | CA2987054A1 (https=) |
| IL (1) | IL255831A (https=) |
| MA (1) | MA42623A (https=) |
| MX (1) | MX2017015574A (https=) |
| RU (1) | RU2017145650A (https=) |
| SG (1) | SG10201911523YA (https=) |
| WO (1) | WO2016196776A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2856248T3 (es) * | 2016-12-21 | 2021-09-27 | Acerta Pharma Bv | Inhibidores de imidazopirazina de la tirosina quinasa de Bruton |
| KR101956815B1 (ko) * | 2017-02-14 | 2019-03-12 | 한국화학연구원 | 트리아졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN109384774B (zh) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用 |
| CN108530450B (zh) * | 2018-05-03 | 2021-03-30 | 赖建智 | 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用 |
| KR102797697B1 (ko) | 2018-05-25 | 2025-04-22 | 에이2에이 파마수티칼스, 잉크. | 신종 항암제 후보로서, 매우 강력한 tacc3 억제제 |
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| AU2019364336B2 (en) | 2018-10-22 | 2023-11-16 | Alumis Inc. | TYK2 inhibitors and uses thereof |
| WO2020167518A1 (en) * | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP3953346A1 (en) | 2019-04-09 | 2022-02-16 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| EP3969447A1 (en) | 2019-05-17 | 2022-03-23 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| BR112022022220A2 (pt) * | 2020-06-01 | 2022-12-13 | Wigen Biomedicine Tech Shanghai Co Ltd | Composto, composição farmacêutica, uso do composto, e método para tratar, regular e/ou prevenir uma doença relacionada a uma proteína mutante de egfr |
| WO2022071772A1 (ko) * | 2020-09-29 | 2022-04-07 | (주)메디톡스 | 단백질 키나제 저해제 및 그의 용도 |
| US12016860B2 (en) | 2021-04-08 | 2024-06-25 | Nurix Therapeutics, Inc. | Combination therapies with Cbl-b inhibitor compounds |
| KR20240005751A (ko) * | 2021-04-12 | 2024-01-12 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
| CN115557933B (zh) * | 2021-07-01 | 2024-08-16 | 杭州和正医药有限公司 | 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用 |
| AU2022379494A1 (en) | 2021-10-26 | 2024-05-30 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| CN116143757B (zh) * | 2021-11-22 | 2024-07-05 | 杭州和正医药有限公司 | 一种可降解btk激酶的多功能化合物、组合物及应用 |
| EP4499625A4 (en) | 2022-03-24 | 2026-03-18 | A2A Pharmaceuticals Inc | CANCER COMPOSITIONS AND TREATMENT METHODS |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5107900A (en) * | 1999-06-09 | 2000-12-28 | Yamanouchi Pharmaceutical Co., Ltd. | Novel heterocyclic carboxamide derivatives |
| JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
| JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| WO2013047813A1 (ja) * | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| EP2763976B1 (en) * | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| CA3094793A1 (en) * | 2011-11-23 | 2013-05-30 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
| WO2013104573A1 (en) * | 2012-01-10 | 2013-07-18 | F. Hoffmann-La Roche Ag | Pyridazine amide compounds and their use as syk inhibitors |
| PL2805940T3 (pl) * | 2012-01-17 | 2017-06-30 | Astellas Pharma Inc. | Związek pirazynokarboksyamidowy |
| US9040530B2 (en) * | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
| US20140113931A1 (en) * | 2012-06-22 | 2014-04-24 | Portola Pharmaceuticals, Inc. | Substituted picolinamide kinase inhibitors |
| HK1217695A1 (zh) * | 2013-03-05 | 2017-01-20 | F. Hoffmann-La Roche Ag | 布鲁顿氏酪氨酸激酶抑制剂 |
| WO2014153280A1 (en) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| WO2015039613A1 (zh) * | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
| AU2014360446A1 (en) * | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
-
2016
- 2016-06-02 BR BR112017025986A patent/BR112017025986A2/pt not_active IP Right Cessation
- 2016-06-02 US US15/579,142 patent/US20180305348A1/en not_active Abandoned
- 2016-06-02 KR KR1020177037849A patent/KR20180021740A/ko not_active Withdrawn
- 2016-06-02 MX MX2017015574A patent/MX2017015574A/es unknown
- 2016-06-02 CA CA2987054A patent/CA2987054A1/en not_active Abandoned
- 2016-06-02 AU AU2016270907A patent/AU2016270907B2/en not_active Ceased
- 2016-06-02 CN CN201680035113.2A patent/CN107709315A/zh active Pending
- 2016-06-02 RU RU2017145650A patent/RU2017145650A/ru not_active Application Discontinuation
- 2016-06-02 SG SG10201911523YA patent/SG10201911523YA/en unknown
- 2016-06-02 EP EP16804424.6A patent/EP3310776A4/en not_active Withdrawn
- 2016-06-02 MA MA042623A patent/MA42623A/fr unknown
- 2016-06-02 WO PCT/US2016/035489 patent/WO2016196776A2/en not_active Ceased
- 2016-06-02 JP JP2017560655A patent/JP2018522823A/ja active Pending
-
2017
- 2017-11-21 IL IL255831A patent/IL255831A/en unknown
-
2019
- 2019-07-17 US US16/514,544 patent/US20210070748A1/en not_active Abandoned
-
2020
- 2020-12-11 AU AU2020286332A patent/AU2020286332A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3310776A2 (en) | 2018-04-25 |
| JP2018522823A (ja) | 2018-08-16 |
| AU2020286332A1 (en) | 2021-01-21 |
| RU2017145650A (ru) | 2019-07-15 |
| KR20180021740A (ko) | 2018-03-05 |
| EP3310776A4 (en) | 2019-01-16 |
| CN107709315A (zh) | 2018-02-16 |
| AU2016270907A1 (en) | 2017-12-07 |
| MA42623A (fr) | 2018-06-20 |
| WO2016196776A2 (en) | 2016-12-08 |
| RU2017145650A3 (https=) | 2019-11-22 |
| BR112017025986A2 (pt) | 2018-08-14 |
| AU2016270907B2 (en) | 2020-09-17 |
| CA2987054A1 (en) | 2016-12-08 |
| WO2016196776A3 (en) | 2017-01-05 |
| SG10201911523YA (en) | 2020-02-27 |
| MX2017015574A (es) | 2018-08-09 |
| US20180305348A1 (en) | 2018-10-25 |
| US20210070748A1 (en) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255831A (en) | Inhibitors of bruton's tyrosine kinase | |
| ZA201903932B (en) | Imidazopyrazine inhibitors of bruton's tyrosine kinase | |
| ZA201907661B (en) | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | |
| ZA201805439B (en) | Bruton's tyrosine kinase inhibitors | |
| IL274716A (en) | Synthesis of a proton tyrosine kinase inhibitor | |
| EP3174539A4 (en) | Inhibitors of bruton's tyrosine kinase | |
| IL250085A0 (en) | New compounds of proton tyrosine kinase inhibitor | |
| IL244492A0 (en) | Broton tyrosine kinase inhibitors | |
| ZA201903694B (en) | Inhibitors of bruton's tyrosine kinase | |
| EP3141546A4 (en) | Inhibitor of bruton's tyrosine kinase | |
| IL248546B (en) | A multi-fluorinated compound as an inhibitor of proton tyrosine kinase | |
| IL259863B (en) | Polycyclic compounds as inhibitors of proton tyrosine kinase | |
| EP3414234A4 (en) | BRUTON TYROSINE KINASE HEMMER | |
| IL261249B1 (en) | Dosage preparations containing Bruton's tyrosine kinase inhibitor | |
| EP3177366A4 (en) | Bruton's tyrosine kinase inhibitor combinations and uses thereof | |
| EP2968341A4 (en) | COMBINATIONS OF BURTON TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS | |
| EP3159340A4 (en) | New bruton's tyrosine kinase inhibitor | |
| EP3273962A4 (en) | Co-crystals of a bruton's tyrosine kinase inhibitor | |
| IL259862B (en) | Inhibitors of proton tyrosine kinase and methods of using them | |
| ZA201906887B (en) | Bruton's tyrosine kinase inhibitors | |
| EP3220912A4 (en) | Tlr inhibitor and bruton's tyrosine kinase inhibitor combinations | |
| EP3273961A4 (en) | Solvated forms of a bruton's tyrosine kinase inhibitor | |
| EP3328380A4 (en) | INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF | |
| HK1260107A1 (en) | Imidazopyrazine inhibitors of bruton's tyrosine kinase | |
| HK40019173A (en) | Inhibitors of bruton's tyrosine kinase |